Cargando…

An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation

BACKGROUND: Laboratory activated partial thromboplastin time (LAB-aPTT) is a widely used laboratory assay for monitoring unfractionated heparin (UFH) therapy during extracorporeal membrane oxygenation (ECMO). But LAB-aPTT is confined to a central laboratory, and the procedure is time-consuming. In c...

Descripción completa

Detalles Bibliográficos
Autores principales: Teng, Yuan, Yan, Shujie, Liu, Gang, Lou, Song, Zhang, Yang, Ji, Bingyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276956/
https://www.ncbi.nlm.nih.gov/pubmed/35847800
http://dx.doi.org/10.3389/fmed.2022.931863
_version_ 1784745833928851456
author Teng, Yuan
Yan, Shujie
Liu, Gang
Lou, Song
Zhang, Yang
Ji, Bingyang
author_facet Teng, Yuan
Yan, Shujie
Liu, Gang
Lou, Song
Zhang, Yang
Ji, Bingyang
author_sort Teng, Yuan
collection PubMed
description BACKGROUND: Laboratory activated partial thromboplastin time (LAB-aPTT) is a widely used laboratory assay for monitoring unfractionated heparin (UFH) therapy during extracorporeal membrane oxygenation (ECMO). But LAB-aPTT is confined to a central laboratory, and the procedure is time-consuming. In comparison, point-of-care aPTT (POC-aPTT) is a convenient and quick assay, which might be a promising method for anticoagulation monitoring in ECMO. This study was aimed to evaluate the agreement between POC-aPTT (hemochron Jr. Signature instruments) and LAB-aPTT for anticoagulation monitoring in adult ECMO patients. METHODS: Data of ECMO-supported adult patients anticoagulated with UFH in our institute from January 2017 to December 2020 was retrospectively reviewed. POC-aPTT and LAB-aPTT results measured simultaneously were paired and included in the analysis. The correlation between POC-aPTT and LAB-aPTT was assessed using Spearman’s correlation coefficient. Bias between POC-aPTT and LAB-aPTT were described with the Bland-Altman method. Influence factors for bias were identified using multinomial logistic regression analysis. RESULTS: A total 286 pairs of aPTT results from 63 patients were included in the analysis. POC-aPTT and LAB-aPTT correlated weakly (r = 0.385, P < 0.001). The overall bias between POC-aPTT and LAB-aPTT was 7.78 [95%CI (−32.49, 48.05)] s. The overall bias between POC-aPTT and LAB-aPTT ratio (to normal value) was 0.54 [95%CI (−0.68, 1.76)]. A higher plasma fibrinogen level [OR 1.353 (1.057, 1.733), P = 0.017] was associated with a higher chance of POC-aPTT underestimating LAB-aPTT. While a lower plasma fibrinogen level [OR 0.809 (0.679, 0.963), P = 0.017] and lower UFH rate [OR 0.928 (0.868, 0.992), P = 0.029] were associated with a higher chance of POC-aPTT overestimating LAB-aPTT. CONCLUSION: The present study showed poor agreement between POC-aPTT and LAB-aPTT. POC-aPTT was not suitable for anticoagulation monitoring in adult ECMO patients.
format Online
Article
Text
id pubmed-9276956
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92769562022-07-14 An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation Teng, Yuan Yan, Shujie Liu, Gang Lou, Song Zhang, Yang Ji, Bingyang Front Med (Lausanne) Medicine BACKGROUND: Laboratory activated partial thromboplastin time (LAB-aPTT) is a widely used laboratory assay for monitoring unfractionated heparin (UFH) therapy during extracorporeal membrane oxygenation (ECMO). But LAB-aPTT is confined to a central laboratory, and the procedure is time-consuming. In comparison, point-of-care aPTT (POC-aPTT) is a convenient and quick assay, which might be a promising method for anticoagulation monitoring in ECMO. This study was aimed to evaluate the agreement between POC-aPTT (hemochron Jr. Signature instruments) and LAB-aPTT for anticoagulation monitoring in adult ECMO patients. METHODS: Data of ECMO-supported adult patients anticoagulated with UFH in our institute from January 2017 to December 2020 was retrospectively reviewed. POC-aPTT and LAB-aPTT results measured simultaneously were paired and included in the analysis. The correlation between POC-aPTT and LAB-aPTT was assessed using Spearman’s correlation coefficient. Bias between POC-aPTT and LAB-aPTT were described with the Bland-Altman method. Influence factors for bias were identified using multinomial logistic regression analysis. RESULTS: A total 286 pairs of aPTT results from 63 patients were included in the analysis. POC-aPTT and LAB-aPTT correlated weakly (r = 0.385, P < 0.001). The overall bias between POC-aPTT and LAB-aPTT was 7.78 [95%CI (−32.49, 48.05)] s. The overall bias between POC-aPTT and LAB-aPTT ratio (to normal value) was 0.54 [95%CI (−0.68, 1.76)]. A higher plasma fibrinogen level [OR 1.353 (1.057, 1.733), P = 0.017] was associated with a higher chance of POC-aPTT underestimating LAB-aPTT. While a lower plasma fibrinogen level [OR 0.809 (0.679, 0.963), P = 0.017] and lower UFH rate [OR 0.928 (0.868, 0.992), P = 0.029] were associated with a higher chance of POC-aPTT overestimating LAB-aPTT. CONCLUSION: The present study showed poor agreement between POC-aPTT and LAB-aPTT. POC-aPTT was not suitable for anticoagulation monitoring in adult ECMO patients. Frontiers Media S.A. 2022-06-29 /pmc/articles/PMC9276956/ /pubmed/35847800 http://dx.doi.org/10.3389/fmed.2022.931863 Text en Copyright © 2022 Teng, Yan, Liu, Lou, Zhang and Ji. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Teng, Yuan
Yan, Shujie
Liu, Gang
Lou, Song
Zhang, Yang
Ji, Bingyang
An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation
title An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation
title_full An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation
title_fullStr An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation
title_full_unstemmed An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation
title_short An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation
title_sort agreement study between point-of-care and laboratory activated partial thromboplastin time for anticoagulation monitoring during extracorporeal membrane oxygenation
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276956/
https://www.ncbi.nlm.nih.gov/pubmed/35847800
http://dx.doi.org/10.3389/fmed.2022.931863
work_keys_str_mv AT tengyuan anagreementstudybetweenpointofcareandlaboratoryactivatedpartialthromboplastintimeforanticoagulationmonitoringduringextracorporealmembraneoxygenation
AT yanshujie anagreementstudybetweenpointofcareandlaboratoryactivatedpartialthromboplastintimeforanticoagulationmonitoringduringextracorporealmembraneoxygenation
AT liugang anagreementstudybetweenpointofcareandlaboratoryactivatedpartialthromboplastintimeforanticoagulationmonitoringduringextracorporealmembraneoxygenation
AT lousong anagreementstudybetweenpointofcareandlaboratoryactivatedpartialthromboplastintimeforanticoagulationmonitoringduringextracorporealmembraneoxygenation
AT zhangyang anagreementstudybetweenpointofcareandlaboratoryactivatedpartialthromboplastintimeforanticoagulationmonitoringduringextracorporealmembraneoxygenation
AT jibingyang anagreementstudybetweenpointofcareandlaboratoryactivatedpartialthromboplastintimeforanticoagulationmonitoringduringextracorporealmembraneoxygenation
AT tengyuan agreementstudybetweenpointofcareandlaboratoryactivatedpartialthromboplastintimeforanticoagulationmonitoringduringextracorporealmembraneoxygenation
AT yanshujie agreementstudybetweenpointofcareandlaboratoryactivatedpartialthromboplastintimeforanticoagulationmonitoringduringextracorporealmembraneoxygenation
AT liugang agreementstudybetweenpointofcareandlaboratoryactivatedpartialthromboplastintimeforanticoagulationmonitoringduringextracorporealmembraneoxygenation
AT lousong agreementstudybetweenpointofcareandlaboratoryactivatedpartialthromboplastintimeforanticoagulationmonitoringduringextracorporealmembraneoxygenation
AT zhangyang agreementstudybetweenpointofcareandlaboratoryactivatedpartialthromboplastintimeforanticoagulationmonitoringduringextracorporealmembraneoxygenation
AT jibingyang agreementstudybetweenpointofcareandlaboratoryactivatedpartialthromboplastintimeforanticoagulationmonitoringduringextracorporealmembraneoxygenation